🇺🇸 FDA
Patent

US 11186626

Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 11186626 (Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop) held by INTEGRATED BIOTHERAPEUTICS, INC. expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INTEGRATED BIOTHERAPEUTICS, INC.
Grant date
Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K39/42, A61K47/6841